Price, AJ; Glynn, J; Chihana, M; Kayuni, N; Floyd, S; Slaymaker, E; Reniers, G; Zaba, B; McLean, E; Kalobekamo, F; Koole, O; Nyirenda, M; Crampin, AC (2016) Sustained 10-year gain in adult life expectancy following antiretroviral therapy roll-out in rural Malawi: July 2005 to June 2014. International journal of epidemiology, 46 (2). pp. 479-491. ISSN 0300-5771 DOI: https://doi.org/10.1093/ije/dyw208

Downloaded from: http://researchonline.lshtm.ac.uk/4046004/

DOI: 10.1093/ije/dyw208

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
HIV Treatment

Sustained 10-year gain in adult life expectancy following antiretroviral therapy roll-out in rural Malawi: July 2005 to June 2014

Alison J Price1*, Judith Glynn1, Menard Chihana3, Ndoliwe Kayuni3, Sian Floyd1, Emma Slaymaker2, Georges Reniers2, Basia Zaba,2 Estelle McLean1, Fredrick Kalobekamo3, Olivier Koole1, Moffat Nyirenda1 and Amelia C Crampin1

1Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK 2Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine and 3Karonga Prevention Study, Chilumba, Karonga, Malawi

*Corresponding author. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. E-mail: alison.price@lshtm.ac.uk

Accepted 28 June 2016

Abstract

Background: Improved life expectancy in high HIV prevalence populations has been observed since antiretroviral therapy (ART) scale-up. However, it is unclear if the benefits are sustained, and the mortality among HIV-positive individuals not (yet) on ART is not well described. We assessed temporal change in mortality over 9 years in rural Malawi.

Methods: Within a demographic surveillance site in northern rural Malawi, we combined demographic, HIV and ART uptake data. We calculated life expectancy using Kaplan-Meier estimates, and compared mortality rates and rate ratios using Poisson regression, by period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014).

Results: Among 32 664 individuals there were 1424 deaths; 1930 individuals were known HIV-positive, of whom 1382 started ART. Overall, life expectancy at age 15 years increased by 10 years within 5 years of ART introduction, and plateaued. Age-standardized adult mortality rates declined from 11.3/1000 to 7.5/1000 person-years between the first and last time period. In July 2011–June 2014 compared with July 2005–June 2008, mortality declined in HIV-positive individuals on ART (rate ratio adjusted (aRR) for age, sex, location and education, 0.3; 95% confidence interval (CI) 0.2–0.5) and in those not (yet) on ART (aRR 0.3; 95%CI 0.1–0.5) but not in HIV-negative individuals (aRR 1.1; 95%CI 0.7–1.9).

Conclusions: Total population adult life expectancy increased toward that of HIV-negative individuals by 2011 and remained raised. The reduction in all-cause and HIV-related mortality in HIV-positive individuals not (yet) on ART suggests ART uptake is occurring at an earlier disease stage, particularly in women.

Key words: HIV, ART, mortality, life-expectancy, Malawi, sub-Saharan Africa

© The Author 2016. Published by Oxford University Press on behalf of the International Epidemiological Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from https://academic.oup.com/ije/article-abstract/46/2/479/2418689 by London School of Hygiene & Tropical Medicine user on 15 January 2018
Introduction

In 2004, Malawi initiated a public health approach to HIV care and treatment services. The programme aimed to deliver antiretroviral therapy (ART) to all eligible HIV-positive individuals presenting to decentralized clinics, with minimal reliance on laboratory support for determining eligibility and for monitoring patients in care. Early success of this initiative was evident within the first year of scale-up, with increased survival among those started on treatment and declines in all-cause mortality rates at the population level.

Since the scale-up of ART programmes, substantial reductions in adult mortality and improved life expectancy among HIV-positive individuals on ART have been observed in other high HIV prevalence sub-Saharan African countries. However, the trends in all-cause and cause-specific mortality patterns in HIV-positive individuals who are not (yet) receiving ART are not well described. Understanding the temporal trends in these different groups is essential for evaluating the impact of future test and treat strategies and establishing whether continued improvement in mortality might be expected in proportion to the increased burden of ART care.

Although introduced nationally in 2004, ART was not available free at the point of care in northern rural Malawi until July 2005. Within a year, all-cause mortality declined by 16% and within the next 2 years, mortality declined by 32%. In this population, deaths attributable to HIV in adults, as assigned by verbal autopsy, decreased from 42% in 2005 to 17% in 2009. It is not clear if these early improvements in mortality are sustained beyond this time, during a period of increasingly decentralized ART care, and where there is little availability of CD4 cell counts or viral load monitoring for those on long-term treatment.

This study uses population-level demographic and HIV test data from northern rural Malawi to investigate the effect of the ART programme on life expectancy and adult all-cause and cause-specific mortality, including HIV-positive individuals with and without ART uptake, covering a 9-year period of scale-up of ART availability through increasingly decentralized care.

Methods

Setting

The Karonga demographic surveillance site (DSS), was established in 2002 in a rural population of nearly 33 000 individuals in northern Malawi, and conducts continuous demographic surveillance, with rigorous identification procedures permitting linkage to data collected in other studies nested within the surveillance population.

HIV counselling and testing (HCT) of the DSS population has been conducted for various studies since 1985. In 2005–06, HIV prevalence was estimated at 11.5% from a population-representative stratified sample sero-survey in those aged 18 to 59 years. Four annual house-to-house cross-sectional HIV sero-surveys were conducted between September 2007 and September 2011, for all individuals aged 15 years or older, involving counselling, enquiry about previous HIV testing and ART uptake start date, and rapid HIV testing with results available to participants. By 2010, HIV prevalence had declined to 8%. In 2013, an additional survey invited participants aged 18 years and older who had missed earlier rounds to screen for HIV infection, using rapid testing with results immediately available.

ART became available in Karonga District Hospital, 70 km north of the DSS area, in July 2005. Within the DSS, ART was first available from a single rural hospital in 2006, then from an additional health centre in 2010 and then from three further health centres between 2011 and early 2012. In the wider Karonga district, there were four ART clinics in 2008, six clinics in 2010 and 16 clinics by the end of 2012. From 2005 to 2010, individuals were eligible for ART if they were in World Health Organization (WHO) clinical stage 3 or 4 or had a CD4 cell count <250 cells/mm³. This was extended to CD4 <350 cells/mm³ in 2011 (and to < 500 cells/mm³ in July 2014, after this study period). Throughout the period of this study, CD4 cell counts were not consistently available and viral load monitoring was not available in the surveillance area. Before and during ART roll-out there was a policy to provide preventative care to all HIV-positive patients, including nutritional support, TB screening and...
treatment and prophylactic cotrimoxazole antibiotics, although delivery was variable.

By mid-2008, ART uptake in the DSS area was estimated to be at least 60% of those eligible, with greater uptake (65%) in women than in men (48%). In the district, 6-month retention in care increased from 70% in the first 2 years of ART availability to 92% in 2011–12.

Data sources

Information relating to an individual’s first ART start date was collected through interviews and linked ART records. If conflicting data were observed between clinic register and self-reported ART start dates, the clinic-register date was used. Individual-level data on pre-ART care was not available for this analysis. HIV test results were obtained from testing conducted in population-level and clinic-based studies between 2005 and 2014. Socio-demographic data, including location of residence (<1 km, ≥1 km to tarmac road) and highest level of education (none/primary incomplete, primary complete, secondary incomplete, secondary complete/tertiary) were obtained from the annual census and continuous demographic surveillance.

Cause of death (HV-related, non-HIV-related) was ascertained from verbal autopsy data. The verbal autopsies are conducted following all deaths in the DSS, by medical assistants with additional training using a semi-structured questionnaire adapted from the standard World Health Organization questionnaire. Whenever possible, the informant is a close relative of the deceased and nursed them through their final illness, and the information is collected approximately 2–4 weeks after the death. Each verbal autopsy questionnaire is independently reviewed by two clinicians, and in the event of discrepancies a third reviewer assigns the cause of death after viewing the initial two reviews. Data on HIV status may be available to the reviewer within the verbal autopsy questionnaire or through access to the HIV test database, if the deceased had participated in a study providing HIV testing. If a decision cannot be made on the cause, the death is coded as un-specified. Of all adult deaths, 9% were either unspecified or unknown.

Statistical analysis

The analysis was restricted to adults aged 15 years or older. To assess life expectancy trends, individuals contributed exposure time during their residence in the DSS from January 2003 (the start of demographic surveillance in the area, including a period preceding population-level HIV testing and ART availability), or their date of in-migration, if later, until the earliest of 31 December 2013, death or out-migration. Adult life expectancy was computed as the area under the Kaplan-Meier survival curve for each calendar year. It can be interpreted as the number of additional years that an adult—here defined as 15 years old—can expect to live under the age- and sex-specific mortality rates that prevail in a particular year.

For all-cause and cause-specific mortality analyses, individuals contributed exposure time during their residence in the DSS from the start of July 2005 (when ART was first available in the district and population-representative HIV test data were available in the DSS), or their date of in-migration if later, until the earliest of 30 June 2014, death or out-migration. Returning and repeat migrants only contributed person-years while resident in the DSS area. HIV status and ART treatment status were treated as time-varying covariates. Person-years were classified as HIV-negative up to 3 years after the latest HIV-negative test unless there was an earlier positive test. Person-years were classified as HIV-positive after a positive test. All other periods (before the first HIV test and >3 years after the latest negative test) were classified as HIV status unknown, to avoid selection bias.

For individuals who reported ART initiation at a clinic outside the district before July 2005, only person-years from study entry at 1 July 2005 contributed to this analysis. ART uptake in HIV-positive individuals was classified according to ever use and duration of treatment. ART uptake in HIV-positive after a positive test. All other periods (before the first HIV test and >3 years after the latest negative test) were classified as HIV status unknown, to avoid selection bias.
education, with adjustment for these factors where appropriate. Likelihood ratio $\chi^2$ tests were used to test for difference in the risk for all-cause and cause-specific deaths in adults over the three calendar periods. Tests for heterogeneity were calculated by entering a term for the interaction between the time period and the co-factor variable in the logistic regression models, and the statistical significance of the interaction terms were calculated with likelihood ratio tests.

These demographic data represent an open cohort, with mortality outcomes available for all those remaining resident in the DSS area. To understand better the extent to which different population sub-groups (who may be at higher risk for death) are associated with risk for departure from the DSS, we conducted an exploratory analysis. All calculations used Stata version 14.0 (Stata Corporation, College Station, TX).

Ethics approval for the studies was granted by the National Health Sciences Research Committee of Malawi (NHSR #419, #424, #448, #968 and #1072) and the Ethics Committee of the London School of Hygiene & Tropical Medicine (#5081, #5067, #5214, #6126 and #6303).

Results

After excluding 11 individuals with indeterminate HIV test results or a single negative test after an earlier positive result, and 26 individuals with an ART start date but a later HIV-negative test result, 14,845 men and 17,819 women aged 15 years and older contributed a total of 161,849 person-years and 1,424 deaths between July 2005 and June 2014. Of 1930 individuals identified as HIV-positive during follow-up, ART uptake was established for 1382 individuals: 1192 (86%) via a clinic register link and 190 (14%) via self-report. Data on WHO stage at ART initiation were available for 97% of those with a clinic register link: initiation at WHO stage four declined from 33% in July 2005–June 2008, to 8% in July 2008–June 2011 and then to 7% in July 2011–June 2014 (data not shown in table).

All-cause adult age-standardized mortality rates declined from 11.3/1000 person-years (py) in July 2005–June 2008, to 10.7/1000 py in July 2008–June 2011 and then to 7.5/1000 py in July 2011–June 2014. Overall life expectancy at age 15 increased from 42.5 (95% CI 37.5–48.4) to 57.9 years (95% CI 53.8–62.1) in men between 2003 and 2010 and from 45.5 (95% CI 39.6–51.5) to 61.8 (95% CI 58.0–66.9) in women between 2003 and 2011, and then plateaued: attaining life expectancy comparable to that observed in HIV-negative men and women (Figure 1a and b).

Age-specific mortality rates and rate ratios in men and women in the three periods of ART availability by sex and 10-year age groups are shown in Table 1. In men and women, mortality was lowest in those aged 15–24 years and highest in those aged 65 years and older, with no evidence for change over time. A large reduction in mortality was observed in women aged 25 to 44 years and men aged 25 to 54 years between the early and mid-period of ART availability. In the late period, these mortality reductions were sustained in women and men aged 25 to 44 years but not in men aged 45 to 54 years.

All-cause crude mortality rates and rate ratios adjusted for sex, age group, location of residence and education are shown in Table 2. After adjusting for other factors there was a 30% reduction in mortality in the adult population between the early and mid-period of ART availability, which was sustained during the late period. Mortality rates were similar in men and women in the early period but a greater reduction was observed in women (30%) than men (20%), although there was no evidence for heterogeneity in the association by sex ($P$-heterogeneity = 0.4). The fall was sustained in both sexes in the late period (July 2011 to June 2014).

Large reductions in mortality were observed in HIV-positive individuals on ART, with crude mortality (CMR) falling from 69.7/1000 py in July 2005–June 2008 to 35.6/1000 py in July 2008–June 2011 to 22.1/1000 py in July 2011–June 2014. A large fall in mortality was observed in HIV-positive individuals not (yet) on ART between the early and middle period (CMR 51.3 vs 12.1/1000 py; aRR 0.2; 95% CI: 0.1–0.4) that was sustained in the late period. Among those who started ART, mortality in the early stages of ART treatment (< 6 months) declined over time from 149.4/1000 py in the early period, to 105.2/1000 py in the middle period and then to 52.0/1000 py in the late period ($P$ = 0.01). There was no evidence for a decline in mortality in those on longer-term treatment (> 6 months) ($P$ = 0.2), or in HIV-negative ($P$ = 0.9) or HIV-unknown individuals ($P$ = 0.2) over the study period, although mortality remained lowest in HIV-negative individuals.

In HIV-positive individuals not (yet) on ART, mortality was higher in women than men in the early period of ART availability and greater mortality reductions were observed in women than in men (53.3 to 13.2 per 1000 py in women vs 48.1 to 19.6 per 1000 py in men), although there was no evidence that the association differed by sex ($P$-heterogeneity = 0.5). Mortality was higher among HIV-positive individuals not on ART and living close to a tarmac road during the early period of ART availability compared with those living further away; however, those close to the tarmac road experienced a greater decline in mortality between the early and late period than those living further
away (69.5 to 13.5/1000 py vs 28.8 to 19.1/1000 py (Table 2). Figure 2a-c shows declining mortality in men and women in the total adult population (Figure 2a) and in HIV-positive individuals (Figure 2b), including men and women not (yet) on ART (Figure 2c).

Table 3 shows that HIV-related mortality in adults declined by 70% between the early and late period of ART availability (CMR 3.4 vs 1.2/1000 py; aRR 0.3; 95% CI: 0.2–0.4), evident in both men and women (P < 0.001). Mortality due to HIV-related causes declined progressively in HIV-positive individuals on treatment, with a 70% lower rate of HIV-related deaths in the late ART period compared with the early period (58.4 vs 17.0 per 1000 py; P < 0.001). Large declines in HIV-related deaths were also observed in HIV-positive individuals not (yet) on ART (70%). In those who ever started ART, early mortality (< 6 months on treatment) due to HIV-related causes dropped from 130.8/1000 py to 54.3/1000 py and then to 45.5/1000 py over the three time periods (P = 0.02).

In this adult population there was no evidence for a decline in non-HIV-related mortality between the early and late time periods of ART availability (Table 4; 6.7 vs 5.6/1000 py; aRR 0.9; 95% CI: 0.8–1.0; P = 0.2), and with no evidence for difference between men and women (P-heterogeneity = 0.4). Between the early and late periods, a large drop in non-HIV-related mortality was observed in HIV-positive individuals not (yet) on treatment (18.0 vs 3.8 per 1000 py; aRR 0.2; 95% CI: 0.1–0.6; P = 0.02) that was not seen in HIV-positive individuals on ART, HIV-negative or HIV-unknown individuals.

Out-migration from the study population was associated with unknown HIV status (aRR HIV unknown vs HIV-negative 2.0; 95% CI: 1.9–2.1), with being younger (aRR 15–24 vs 65 years or older 8.1; 95% CI: 7.2–9.2); with female sex (aRR female vs male 1.2; 95% CI: 1.2–1.3), and; with higher educational attainment (aRR secondary vs none/incomplete primary 4.2; 95% CI: 3.6–4.8; results not shown in a table), after controlling for potential confounders.

![Figure 1. Life expectancy at 15 years in women (a) and men (b): 2003-2013.](https://academic.oup.com/ije/article-abstract/46/2/479/2418689)
Discussion

Our data show that total population adult life expectancy at age 15 in rural northern Malawi increased by almost 10 years between 2005 and 2011 and then plateaued, reaching the life expectancy estimate of HIV-negative individuals. Our results are of a similar or greater magnitude to the increases in mean length of life observed elsewhere in high HIV prevalence sub Saharan Africa where national ART programmes exist.\textsuperscript{7,21} In our population, the observed increase in adult life expectancy is largely a result...
Table 1. Age specific mortality rates for adults 15 years and older by sex and period of ART availability

| Person-years | Deaths | Rate/1000 py | 95% CI | Crude mortality rate ratio | 95% CI | Adjusted mortality rate ratio<sup>a</sup> | 95% CI | P-value<sup>b</sup> |
|--------------|--------|-------------|--------|---------------------------|--------|--------------------------------|--------|------------------|
| **Male, age, years** | | | | | | | | |
| 15–24 | | | | | | | | |
| Jul 05–Jun 08 | 8940 | 14 | 1.6 | 0.9–2.6 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 8910 | 14 | 1.6 | 0.9–2.7 | 1.0 | 0.5–2.1 | 1.1 | 0.5–2.2 |
| Jul 11–Jun 14 | 9968 | 18 | 1.8 | 1.1–2.9 | 1.2 | 0.6–2.3 | 1.2 | 0.6–2.3 0.9 |
| 25–34 | | | | | | | | |
| Jul 05–Jun 08 | 6220 | 46 | 7.4 | 5.5–9.9 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 6316 | 24 | 3.8 | 2.5–5.7 | 0.5 | 0.3–0.8 | 0.5 | 0.3–0.9 |
| Jul 11–Jun 14 | 6534 | 25 | 3.8 | 2.6–5.7 | 0.5 | 0.3–0.8 | 0.5 | 0.3–0.9 0.01 |
| 35–44 | | | | | | | | |
| Jul 05–Jun 08 | 3521 | 58 | 16.5 | 12.7–21.3 | 1.0 | | | 1 |
| Jul 08–Jun 11 | 3968 | 33 | 8.3 | 5.9–11.7 | 0.5 | 0.3–0.8 | 0.5 | 0.3–0.8 |
| Jul 11–Jun 14 | 4520 | 47 | 10.4 | 7.8–13.8 | 0.6 | 0.4–0.9 | 0.6 | 0.4–0.9 0.004 |
| 45–54 | | | | | | | | |
| Jul 05–Jun 08 | 2006 | 41 | 20.4 | 15.1–27.8 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 2311 | 19 | 8.2 | 5.2–12.9 | 0.4 | 0.2–0.7 | 0.4 | 0.2–0.7 |
| Jul 11–Jun 14 | 2630 | 35 | 13.3 | 9.6–18.5 | 0.7 | 0.4–1.0 | 0.7 | 0.4–1.1 0.004 |
| 55–64 | | | | | | | | |
| Jul 05–Jun 08 | 1319 | 32 | 24.3 | 17.2–34.3 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 1347 | 27 | 20.0 | 13.7–29.2 | 0.8 | 0.5–1.4 | 0.9 | 0.5–1.4 |
| Jul 11–Jun 14 | 1475 | 19 | 12.9 | 8.2–20.2 | 0.5 | 0.3–0.9 | 0.6 | 0.3–1.0 0.1 |
| 65+ | | | | | | | | |
| Jul 05–Jun 08 | 1698 | 75 | 44.2 | 35.2–55.4 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 1739 | 94 | 54.0 | 44.1–66.1 | 1.2 | 0.9–1.7 | 1.3 | 1.0–1.8 |
| Jul 11–Jun 14 | 1855 | 75 | 40.4 | 32.2–50.7 | 0.9 | 0.7–1.3 | 1.0 | 0.7–1.4 0.2 |
| **Female, age, years** | | | | | | | | |
| 15–24 | | | | | | | | |
| Jul 05–Jun 08 | 9356 | 13 | 1.4 | 0.8–2.4 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 9477 | 15 | 1.6 | 1.0–2.6 | 1.1 | 0.5–2.4 | 1.3 | 0.6–2.8 |
| Jul 11–Jun 14 | 10698 | 18 | 1.7 | 1.1–2.7 | 1.2 | 0.6–2.5 | 1.4 | 0.7–2.9 0.6 |
| 25–34 | | | | | | | | |
| Jul 05–Jun 08 | 6894 | 64 | 9.3 | 7.3–11.9 | 1.0 | | | 1 |
| Jul 08–Jun 11 | 7298 | 23 | 3.2 | 2.1–4.7 | 0.3 | 0.2–0.5 | 0.3 | 0.2–0.6 |
| Jul 11–Jun 14 | 7802 | 21 | 2.7 | 1.8–4.1 | 0.3 | 0.2–0.5 | 0.3 | 0.2–0.5 < 0.001 |
| 35–44 | | | | | | | | |
| Jul 05–Jun 08 | 3933 | 42 | 10.7 | 7.9–14.5 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 4359 | 24 | 5.5 | 3.7–8.2 | 0.5 | 0.3–0.9 | 0.5 | 0.3–0.9 |
| Jul 11–Jun 14 | 5156 | 19 | 3.7 | 2.4–5.8 | 0.3 | 0.2–0.6 | 0.4 | 0.2–0.6 0.001 |
| 45–54 | | | | | | | | |
| Jul 05–Jun 08 | 2640 | 30 | 11.4 | 7.9–16.3 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 2860 | 22 | 7.7 | 5.1–11.7 | 0.7 | 0.4–1.2 | 0.7 | 0.4–1.2 |
| Jul 11–Jun 14 | 3149 | 24 | 7.6 | 5.1–11.4 | 0.7 | 0.4–1.1 | 0.7 | 0.4–1.2 0.3 |
| 55–64 | | | | | | | | |
| Jul 05–Jun 08 | 1791 | 34 | 19.0 | 13.6–26.6 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 1929 | 20 | 10.4 | 6.7–16.1 | 0.5 | 0.3–0.9 | 0.6 | 0.3–1.0 |
| Jul 11–Jun 14 | 2043 | 22 | 10.8 | 7.1–16.4 | 0.6 | 0.3–1.0 | 0.6 | 0.3–1.0 0.1 |
| 65+ | | | | | | | | |
| Jul 05–Jun 08 | 2254 | 118 | 52.4 | 43.7–62.7 | 1.0 | | | 1.0 |
| Jul 08–Jun 11 | 2342 | 102 | 43.5 | 35.9–52.9 | 0.8 | 0.6–1.1 | 0.8 | 0.6–1.1 |
| Jul 11–Jun 14 | 2591 | 117 | 45.2 | 37.7–54.1 | 0.9 | 0.7–1.1 | 0.9 | 0.7–1.1 0.4 |

py, person-years; June, June; Jul, July; -, range.

<sup>a</sup>Adjustment made for location of residence (< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

<sup>b</sup>P-value test for difference in the association between time-period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and mortality, calculated with a likelihood ratio test.
## Table 2. All-cause mortality for adults aged 15 years and older by period of ART availability and HIV infection/ART use

|                      | Person-years | Deaths | Rate/1000 py | 95% CI | Crude mortality rate ratio | 95% CI | Adjusted mortality rate ratio | 95% CI | Adjusted mortality rate ratio | 95% CI | P-value |
|----------------------|--------------|--------|--------------|--------|---------------------------|--------|-----------------------------|--------|-----------------------------|--------|---------|
| **Overall population** |              |        |              |        |                          |        |                             |        |                             |        |         |
| **Period of ART**     |              |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 50571        | 567    | 11.2         | 9.5–12.2 | 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 52857        | 417    | 7.9          | 7.2–8.7 | 0.7                       | 0.6–0.8| 0.7                         | 0.6–0.8| 0.7                         | 0.6–0.8| < 0.001 |
| Jul 11–Jun 14         | 58421        | 440    | 7.5          | 6.9–8.3 | 0.7                       | 0.6–0.8| 0.7                         | 0.6–0.8| 0.7                         | 0.6–0.8|         |
| **Sex by period of ART** |            |        |              |        |                          |        |                             |        |                             |        |         |
| Male                  |              |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 23703        | 266    | 11.2         | 10.0–12.7| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 245915       | 211    | 8.6          | 7.5–9.8 | 0.8                       | 0.6–0.9| 0.8                         | 0.6–0.9| 0.8                         | 0.6–0.9| < 0.004 |
| Jul 11–Jun 14         | 269812       | 219    | 8.1          | 7.1–9.3 | 0.7                       | 0.6–0.9| 0.7                         | 0.6–0.9| 0.8                         | 0.6–0.9|     |
| Female                |              |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 26868        | 301    | 11.2         | 10.0–12.5| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 28266        | 206    | 7.3          | 6.4–8.4 | 0.7                       | 0.5–0.8| 0.6                         | 0.5–0.8| 0.7                         | 0.6–0.8| < 0.001 |
| Jul 11–Jun 14         | 31439        | 221    | 7.0          | 6.2–8.0 | 0.6                       | 0.5–0.7| 0.6                         | 0.5–0.7| 0.7                         | 0.5–0.8|         |
| **HIV infection/ART use by period of ART** |              |        |              |        |                          |        |                             |        |                             |        |         |
| HIV-negative          |              |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 4876         | 17     | 3.5          | 2.2–5.6 | 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 35080        | 173    | 4.9          | 4.2–5.7 | 1.4                       | 0.9–2.3| 1.1                         | 0.7–1.8| 1.1                         | 0.7–1.8|         |
| Jul 11–Jun 14         | 32700        | 162    | 5.0          | 4.2–5.8 | 1.4                       | 0.9–2.3| 1.1                         | 0.7–1.8| 1.1                         | 0.7–1.9|         |
| HIV-positive; ever on ART |            |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 531          | 37     | 69.7         | 50.5–96.1| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 1771         | 63     | 35.6         | 27.8–45.5| 0.5                       | 0.3–0.8| 0.5                         | 0.3–0.7| 0.5                         | 0.3–0.7|         |
| Jul 11–Jun 14         | 2710         | 60     | 22.1         | 17.2–28.5| 0.3                       | 0.2–0.5| 0.3                         | 0.2–0.5| 0.3                         | 0.2–0.5| < 0.001 |
| HIV-positive; not (yet) on ART |         |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 390          | 20     | 51.3         | 33.1–79.5| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 1484         | 18     | 12.1         | 7.6–19.3 | 0.2                       | 0.1–0.4| 0.2                         | 0.1–0.4| 0.2                         | 0.1–0.4|         |
| Jul 11–Jun 14         | 1064         | 17     | 16.0         | 10.0–25.7| 0.3                       | 0.2–0.6| 0.3                         | 0.1–0.5| 0.3                         | 0.1–0.5| < 0.001 |
| HIV status unknown    |              |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 44742        | 493    | 11.0         | 10.1–12.0| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 14523        | 163    | 11.2         | 9.6–13.1 | 1.0                       | 0.9–1.2| 0.9                         | 0.8–1.1| 1.0                         | 0.8–1.1|         |
| Jul 11–Jun 14         | 21947        | 201    | 9.2          | 8.0–10.5 | 0.8                       | 0.7–1.0| 0.8                         | 0.7–1.0| 0.9                         | 0.7–1.0| 0.2     |
| HIV-positive ever on ART |            |        |              |        |                          |        |                             |        |                             |        |         |
| HIV-positive; < 6 months on treatment |          |        |              |        |                          |        |                             |        |                             |        |         |
| Jul 05–Jun 08         | 160          | 24     | 149.4        | 100.2–222.9| 1.0                       | 1.0    |                             | 1.0    |                             | 1.0    |         |
| Jul 08–Jun 11         | 238          | 25     | 105.2        | 71.8–155.7| 0.7                       | 0.4–1.2| 0.7                         | 0.4–1.2| 0.7                         | 0.4–1.2|         |
| Jul 11–Jun 14         | 154          | 8      | 52.0         | 26.0–103.9| 0.3                       | 0.2–0.8| 0.3                         | 0.2–0.8| 0.3                         | 0.1–0.7| 0.01    |
Table 2. Continued

| Person-years | Deaths | Rate/1000 py | 95% CI | Crude | 95% CI | Adjusted | 95% CI | Adjusted | 95% CI | Adjusted | 95% CI | P-value |
|--------------|--------|-------------|--------|--------|--------|----------|--------|----------|--------|----------|--------|---------|
| HIV-positive; ≥ 6 months on treatment | | | | | | | | | | | | |
| Jul 05–Jun 08 | 371 | 13 | 35.1 | 20.4–60.4 | 1.0 | 1.0 | 1.0 | 0.20 |
| Jul 08–Jun 11 | 1533 | 38 | 24.8 | 18.0–34.1 | 0.7 | 0.4–1.3 | 0.7 | 0.3–1.2 |
| Jul 11–Jun 14 | 2586 | 52 | 20.3 | 15.5–26.7 | 0.6 | 0.3–1.1 | 0.5 | 0.3–1.0 |
| HIV-positive; not (yet) on ART | | | | | | | | | | | | |
| Male | | | | | | | | | | | | |
| Jul 05–Jun 08 | 146 | 7 | 48.1 | 22.9–100.9 | 1.0 | 1.0 | 1.0 | 0.40 |
| Jul 08–Jun 11 | 571 | 10 | 17.5 | 9.4–32.6 | 0.4 | 0.1–1.0 | 0.4 | 0.1–0.9 |
| Jul 11–Jun 14 | 458 | 9 | 19.6 | 10.2–37.8 | 0.4 | 0.2–1.1 | 0.4 | 0.1–1.0 |
| Female | | | | | | | | | | | | |
| Jul 05–Jun 08 | 244 | 13 | 53.3 | 30.9–91.7 | 1.0 | 1.0 | 1.0 | <0.001 |
| Jul 08–Jun 11 | 913 | 8 | 8.8 | 4.4–17.5 | 0.2 | 0.1–0.4 | 0.1 | 0.1–0.4 |
| Jul 11–Jun 14 | 606 | 8 | 13.2 | 6.6–26.4 | 0.2 | 0.1–0.6 | 0.2 | 0.1–0.5 |
| HIV-positive; not (yet) on ART | | | | | | | | | | | | |
| Location of residence < 1 km from tarmac | | | | | | | | | | | | |
| Male | | | | | | | | | | | | |
| Jul 05–Jun 08 | 216 | 15 | 69.5 | 41.9–115.2 | 1.0 | 1.0 | 1.0 | 0.04–0.3 |
| Jul 08–Jun 11 | 779 | 6 | 7.7 | 3.5–17.1 | 0.1 | 0.04–0.3 | 0.1 | 0.04–0.3 |
| Jul 11–Jun 14 | 593 | 8 | 13.5 | 6.7–27.0 | 0.2 | 0.1–0.5 | 0.2 | 0.1–0.4 |
| Female | | | | | | | | | | | | |
| Jul 05–Jun 08 | 171 | 5 | 28.8 | 12.0–69.1 | 1.0 | 1.0 | 1.0 | 0.1–0.4 |
| Jul 08–Jun 11 | 674 | 12 | 17.0 | 9.7–30.0 | 0.6 | 0.2–1.7 | 0.5 | 0.2–1.5 |
| Jul 11–Jun 14 | 456 | 9 | 19.1 | 9.9–36.7 | 0.7 | 0.2–2.0 | 0.5 | 0.2–1.6 |

Jun, June; Jul, July; py, person-years; -, range.

*aAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), where appropriate.

*bAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), location of residence (< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

*cP-value test for difference in the association between period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and mortality, calculated with a likelihood ratio test.

*dIn those who used ART during follow-up, the data are presented by duration of treatment (< 6 and ≥ 6 months).
of the decline in adult mortality of HIV-positive individuals during a 9-year period of ART scale-up, decentralized care and annual household-level HIV testing, with almost universal acceptance of test results.\textsuperscript{16,22}

The large reductions in all-cause and HIV-related mortality over time in those not (yet) on ART indicates a shift in ART initiation, from late-stage AIDS to an earlier phase of infection, getting HIV-positive individuals onto treatment early, leaving only relatively healthy positive individuals without (or yet to start) treatment. The sustained reduction in mortality over time in HIV-positive individuals and reduction in HIV-related mortality are consistent with our earlier findings\textsuperscript{13} and confirm that the early success of the ART programme\textsuperscript{12} has continued over the

| Person-years | HIV-related deaths | Rate/1000 py | 95% CI | Crude mortality rate ratio | 95% CI | Adjusted mortality rate ratio\textsuperscript{a} | 95% CI | Adjusted mortality rate ratio\textsuperscript{b} | 95% CI | P-value\textsuperscript{c} |
|-------------|-------------------|-------------|-------|---------------------------|-------|--------------------------------|-------|--------------------------------|-------|-----------|
| Overall population |
| Period of ART |
| Jul 05–Jun 08 | 50571 | 174 | 3.4 | 3.0–4.0 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 52857 | 73 | 1.4 | 1.1–1.7 | 0.4 | 0.3–0.5 | 0.4<br>Jul 11–Jun 14 | 58421 | 69 | 1.2 | 0.9–1.5 | 0.3 | 0.3–0.5 | 0.3<br>
| Sex |
| Male |
| Jul 05–Jun 08 | 23703 | 91 | 3.8 | 3.1–4.7 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 24592 | 37 | 1.5 | 1.1–2.1 | 0.4 | 0.3–0.6 | 0.4<br>Jul 11–Jun 14 | 26981 | 35 | 1.3 | 0.9–1.8 | 0.3 | 0.2–0.5 | 0.3<br>
| Female |
| Jul 05–Jun 08 | 26868 | 83 | 3.1 | 2.5–3.8 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 28266 | 36 | 1.3 | 0.9–1.8 | 0.4 | 0.3–0.6 | 0.4<br>Jul 11–Dec 13 | 31439 | 34 | 1.1 | 0.8–1.5 | 0.4 | 0.2–0.5 | 0.3<br>
| HIV infection/ART use by period of ART |
| HIV-positive; ever on ART |
| Jul 05–Jun 08 | 531 | 31 | 58.4 | 41.0–83.0 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 1771 | 51 | 38.8 | 21.9–37.9 | 0.5 | 0.3–0.8 | 0.5<br>Jul 11–Jun 14 | 2710 | 46 | 17.0 | 12.7–22.7 | 0.3 | 0.2–0.5 | 0.3<br>
| HIV-positive; not (yet) on ART |
| Jul 05–Jun 08 | 390 | 12 | 30.8 | 17.5–54.2 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 1485 | 9 | 6.1 | 3.2–11.7 | 0.2 | 0.1–0.5 | 0.2<br>Jul 11–Jun 14 | 1064 | 11 | 10.3 | 5.7–18.7 | 0.3 | 0.1–0.8 | 0.3<br>
| HIV status unknown |
| Jul 05–Jun 08 | 44742 | 131 | 2.9 | 2.5–3.5 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 14523 | 12 | 0.8 | 0.5–1.5 | 0.3 | 0.2–0.5 | 0.3<br>Jul 11–Jun 14 | 21947 | 12 | 0.5 | 0.3–1.0 | 0.2 | 0.1–0.3 | 0.2<br>
| HIV-positive ever on ART\textsuperscript{d} |
| HIV test positive; < 6 months on treatment |
| Jul 05–Jun 08 | 161 | 21 | 130.8 | 85.3–200.5 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 238 | 20 | 54.3 | 54.3–130.5 | 0.6 | 0.3–1.2 | 0.6<br>Jul 11–Jun 14 | 154 | 7 | 45.5 | 20.7–95.4 | 0.3 | 0.1–0.8 | 0.3<br>
| HIV test positive; ≥ 6 months on treatment |
| Jul 05–Jun 08 | 371 | 10 | 27.0 | 14.3–50.2 | 1.0 | 1.0 | 1.0<br>Jul 08–Jun 11 | 1533 | 31 | 20.2 | 14.2–28.7 | 0.7 | 0.4–1.5 | 0.7<br>Jul 11–Jun 14 | 2556 | 39 | 15.3 | 11.1–20.9 | 0.6 | 0.3–1.1 | 0.5<br>

\textsuperscript{a}Adjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), where appropriate.

\textsuperscript{b}Adjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), location of residence (< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

\textsuperscript{c}P-value test for difference in the association between period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and mortality, calculated with a likelihood ratio test.

\textsuperscript{d}In those who used ART during follow-up, the data are presented by duration of treatment (< 6 and ≥ 6 months).
longer term in this rural, resource-constrained setting. However, our results suggest that smaller gains are being made in men than in women, particularly among those who are HIV-positive and yet to start ART. These findings indicate that men with a positive HIV diagnosis are remaining, to a greater extent than women, without treatment until too late into the disease: a finding consistent with other studies from sub-Saharan Africa.  

Table 4. Non-HIV-related mortality for adults 15 years and older by period of ART availability and HIV infection/ART use

| Period of ART | Person-years | Non-HIV-related deaths | Rate/1000 py | 95% CI | Crude mortality rate ratio | 95% CI | Adjusted mortality rate ratio | 95% CI | Adjusted mortality rate ratio | 95% CI | P-value |
|---------------|--------------|------------------------|-------------|--------|---------------------------|--------|-----------------------------|--------|-----------------------------|--------|---------|
| Overall population
| Jul 05–Jun 08 | 50571        | 341                    | 6.7         | 6.1–7.5 | 1.0                       | 1.0    | 1.0                         | 1.0    | 1.0                         | 1.0    |         |
| Jul 08–Jun 11 | 52837        | 313                    | 5.9         | 5.3–6.6 | 0.9                       | 0.8–1.0 | 0.9                         | 0.8–1.0 | 0.9                         | 0.8–1.1 |         |
| Jul 11–Jun 14 | 58421        | 325                    | 5.6         | 5.0–6.2 | 0.8                       | 0.7–1.0 | 0.8                         | 0.7–1.0 | 0.9                         | 0.8–1.0 | 0.2     |
| Sex
| Male
| Jul 05–Jun 08 | 23703        | 154                    | 6.5         | 5.5–7.6 | 1.0                       | 1.0    | 1.0                         | 1.0    | 1.0                         | 1.0    |         |
| Jul 08–Jun 11 | 24592        | 158                    | 6.4         | 5.5–7.5 | 1.0                       | 0.8–1.2 | 1.0                         | 0.8–1.2 | 1.03                        | 0.8–1.3 |         |
| Jul 11–Jun 14 | 26981        | 163                    | 6.0         | 5.2–7.0 | 0.9                       | 0.7–1.2 | 0.9                         | 0.7–1.2 | 1.00                        | 0.8–1.2 | 1.00    |
| Female
| Jul 05–Jun 08 | 26868        | 187                    | 7.0         | 6.0–8.0 | 1.0                       | 1.0    | 1.0                         | 1.0    | 1.0                         | 1.0    |         |
| Jul 08–Jun 11 | 28266        | 155                    | 5.5         | 4.7–6.4 | 0.8                       | 0.6–1.0 | 0.8                         | 0.6–1.0 | 0.8                         | 0.7–1.0 |         |
| Jul 11–Jun 14 | 31439        | 162                    | 5.2         | 4.4–6.0 | 0.7                       | 0.6–0.9 | 0.7                         | 0.6–0.9 | 0.8                         | 0.6–1.0 | 0.04    |

HIV infection/ART use by period of ART

| HIV status unknown
| Jul 05–Jun 08 | 44774        | 313                    | 7.0         | 6.3–7.8 | 1.0                       | 1.0    | 1.0                         | 1.0    | 1.0                         | 1.0    |         |
| Jul 08–Jun 11 | 14523        | 136                    | 9.4         | 7.9–11.1| 1.3                       | 1.1–1.6 | 1.2                         | 1.0–1.5 | 1.2                         | 1.0–1.5 |         |
| Jul 11–Jun 14 | 21947        | 160                    | 7.3         | 6.2–8.5 | 1.0                       | 0.9–1.3 | 1.0                         | 0.8–1.2 | 1.1                         | 0.9–1.3 | 0.10    |

HIV-positive ever on ART

| HIV test positive; < 6 months on treatment
| Jul 05–Jun 08 | 161          | 3                      | 18.7        | 6.0–54.5 | 1.0                       | 1.0    | 1.0                         | 1.0    | 1.0                         | 1.0    |         |
| Jul 08–Jun 11 | 238          | 4                      | 16.8        | 6.4–45.3 | 0.9                       | 0.2–4.0 | 0.9                         | 0.2–3.9 | 0.9                         | 0.2–4.1 |         |
| Jul 11–Jun 14 | 154          | 1                      | 6.5         | 6.0–50.4 | 0.3                       | 0.04–3.3| 0.3                         | 0.04–3.3 | 0.3                         | 0.04–3.3 | 0.6     |

P-value test for difference in the association between period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and mortality, calculated with a likelihood ratio test.

a Adjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), where appropriate.

b Adjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65+ years), sex (male, female), location of residence (< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

c In those who used ART during follow-up, the data are presented by duration of treatment (< 6 and ≥ 6 months).
setting, the late treatment occurred even though the individuals were aware of their HIV status, an issue that may be important to consider as the global impetus for achieving 90-90-90 targets intensifies, requiring initiation of ART immediately after testing HIV positive.\textsuperscript{10,11} 

Among HIV-positive individuals, the initially high mortality in the first 6 months of treatment more than halved over time as individuals moved onto treatment at an earlier stage of disease (evidenced by 7% initiating ART in WHO stage 4 in the late phase, compared with 33% in the early phase); but it remained a high-risk period, as observed elsewhere.\textsuperscript{24} The large decline in HIV-related deaths in those of unknown HIV status suggests that few undiagnosed HIV-positive individuals remain in the surveillance population, following high participation rates in multiple HIV sero-surveys, during which 95% received their results.\textsuperscript{16} Access difficulties, including distance to clinics and transport costs, are established barriers for linkage to and retention in care.\textsuperscript{25} In Malawi, decentralization of ART services is associated with improved retention of patients in care.\textsuperscript{17} However, lower declines in all-cause and HIV-related mortality were observed in those living in more rural areas compared with those living close to a tarmac road, which may suggest more unmet need peripherally despite decentralization.

Our study linked annual sero-survey HIV test results and ART clinic data from across the surveillance population, which facilitated categorization of individuals according to HIV status and ART uptake to investigate in detail the impact of ART on mortality over time. However, our data include a relatively small HIV-positive adult population, so the confidence intervals on our mortality estimates are wide, particularly for age-group categories and other sub-group analyses. Nonetheless, HIV testing was provided in the community to a population representative sample between 2005 and 2006 and across all adults (15 years and older) between 2007 and 2011, so selection bias should not be a major concern for our study. HIV-unknown individuals contributed the largest proportion of person-years in the early phase of ART availability but, since HIV testing across the entire population did not start until 2007, the unknown population is likely to be representative of the overall population. Inclusion of undiagnosed, late-stage HIV-positive individuals in the HIV-unknown group will have contributed to the higher HIV-related mortality in the early period compared with the late period, when fewer chronically undiagnosed HIV-positive individuals remain in the population. Adults of unknown HIV status, young individuals, women and those with higher educational attainment were most at risk of out-migration from the DSS. Data on the health status of out-migrants at the time of departure (or their subsequent survival or death) were not available, so the extent to which their departure affected our mortality and life expectancy estimates could not be determined. However, in other settings where tracking of out-migrants has been implemented, higher mortality in those individuals has been reported,\textsuperscript{26} so it is possible that our results (and those from other DSS and open cohort studies) somewhat underestimate mortality and overestimate life expectancy gains. It is also possible that compared with the general population, higher life expectancy gains were observed in our surveillance population where health-related research has been conducted for many years. We have previously shown that during this time period, an increasing proportion of verbal autopsy informants reported that they knew the deceased’s HIV status, and the HIV status recorded on the verbal autopsy report influences the way the clinician reviewer assigns cause of death irrespective of symptoms.\textsuperscript{27} Hence it is possible that our findings underestimate to some extent the true gains in HIV-related mortality although, given the stable estimates of non-HIV-related mortality, misclassification is unlikely to be a major issue.

As the numbers of infected individuals surviving on ART increase; long-term retention and adherence; onward transmission from those who have interrupted treatment; and, identification of virological failure in long-term ART users, will be a challenge for the current public health programme and require ongoing monitoring and evaluation. In 2011, Malawi expanded the criteria for ART eligibility to include HIV-positive individuals with CD4 counts < 350 cell/mm\textsuperscript{3}, and initiation of life-long treatment in pregnant and breastfeeding women irrespective of disease severity,\textsuperscript{28} and to HIV-positive individuals with CD4 counts < 500/ mm\textsuperscript{3} from July 2014 onwards.\textsuperscript{29} These changes facilitate earlier initiation and increase the numbers of individuals alive on ART, but the sustained gains in adult life expectancy depend on continued access to effective treatment and high levels of retention and adherence of those in care. With a growing number of individuals surviving on ART, early identification of virological failure with the option to switch treatment at decentralized clinics is needed but will be a challenge in this setting.

Conclusions

Our results suggest that large reductions in adult mortality and increasing adult life expectancy have been achieved in rural Malawi over a 9-year period of ART availability, as HIV infected individuals move into care at an earlier stage of disease. HIV-positive men may be more likely than women to remain without ART until a late stage of disease. These data confirm that the success achieved in the early phase of ART availability has continued, highlighting the success of the public health approach to HIV care in
Malawi. Improvement in mortality was observed in those who have accessed care and also in those not yet in care.

Funding
This work was supported by a Wellcome Trust Award (096249/Z/11/A).

Conflict of interest: None to declare.

References
1. Ministry of Health National AIDS Commission. Treatment of AIDS Guidelines for the Use of Antiretroviral Therapy in Malawi. 1st edn. Lilongwe, Malawi: Ministry of Health, 2003.
2. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006;367:1870–72.
3. Lowrance DW, Makombe S, Harries AD et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004–2006. J Acquir Immune Defic Syndr 2008;49:287–93.
4. Jahn A, Floyd S, Crampin AC et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008;371:1603–11.
5. Reniers G, Slaymaker E, Nakiyimi-Miuro J et al. Mortality trends in the era of antiretroviral therapy: Evidence from the network for analysing longitudinal population based HIV/AIDS data on Africa (ALPHA). AIDS 2014;28:5333–42.
6. Mills EJ, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Intern Med 2011;155:209–17.
7. Bor J, Herbst AJ, Newell M, Bärnighausen T. Increases in adult life expectancy in rural South Africa: Valuing the scale-up of HIV treatment. Science 2013;339:961–65.
8. Johnson LF, Mossong J, Dormington RE et al. Life Expectancies of South African adults starting antiretroviral treatment: A collaborative analysis of cohort studies. PLoS Med 2013;10:e1001418.
9. Nsanzimana S, Remera E, Kanter S et al. Life expectancy among HIV-positive patients in Rwanda: A retrospective observational cohort study. Lancet Glob Health 2015;3:e169–77.
10. Danel C, Moh R, Galibard D et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015;373:808–22.
11. Lundgren JD, Babiker AG, Gordin F et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795–807.
12. Floyd S, Molesworth A, Dube A et al. Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in Northern Malawi. PLoS One 2010;5:e13499.
13. Chihana M, Floyd S, Molesworth A et al. Adult mortality and probable cause of death in rural northern Malawi in the era of HIV treatment. Trop Med Int Health 2012;17:e74–83.
14. Crampin AC, Dube A, Mboma S et al. Profile: The Karonga health and demographic surveillance system. Int J Epidemiol 2012;41:676–85.
15. McGrath N, Kranzer K, Saul J et al. Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. AIDS 2007;21(Suppl 6):S105–13.
16. Floyd S, Molesworth A, Dube A et al. Underestimation of HIV prevalence in surveys when some people already know their status, and ways to reduce the bias. AIDS 2013;27:233–42.
17. Koole O, Houwen RMGJ, Mzembe T et al. Improved retention of patients starting antiretroviral treatment in Karonga District, Northern Malawi, 2005–2012. J Acquir Immune Defic Syndr 2014;67:e27–33.
18. Wringe A, Floyd S, Kazooba P et al. Antiretroviral therapy uptake and coverage in four HIV community cohort studies in sub-Saharan Africa. Trop Med Int Health 2012;17:e38–48.
19. van Lettow M, Åkesson A, Martiniuk ALC et al. Six-month mortality among HIV-infected adults presenting for antiretroviral therapy with unexplained weight loss, chronic fever or chronic diarrhea in Malawi. PLoS One 2012;7:e48856.
20. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22:1897–908.
21. Asiki G, Reniers G, Newton R et al. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991–2012). AIDS 2016;30:487–93.
22. Floyd S, Marston M, Baisley K et al. The effect of antiretroviral therapy provision on all-cause, AIDS and non-AIDS mortality at the population level – a comparative analysis of data from four settings in Southern and East Africa. Trop Med Int Health 2012;17:e84–91.
23. Mills EJ, Bakanda C, Birungi J et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011;14:52.
24. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): A systematic review and meta-analysis. PLoS One 2011;6:e28691.
25. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: A systematic review. AIDS 2012;26:2059–67.
26. Sewankambo NK, Gray RH, Ahmad S et al. Mortality associated with HIV infection in rural Rakai District, Uganda. AIDS 2000;14:2391–400.
27. McLean EM, Chihana M, Mzembe T et al. Reliability of reporting of HIV status and ART usage during verbal autopsies: a large prospective study in rural Malawi. Glob Health Action 2016;9:31084.
28. Ministry of Health. Clinical Management of HIV in Children and Adults. Lilongwe, Malawi: Malawi Ministry of Health, 2011.
29. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for treating and Preventing HIV Infection. Recommendations for a Public Health Approach 2013: Supplement. Geneva: WHO, 2014.